Publications de 2016

1

Evolution of renal function in African patients initiating second line antiretroviral treatment : Findings from the 2LADY-ANRS 12169 trial

Cournil A, Hema A, Eymard-DuvernayS, Ciaffi L, Badiou S, Kabore F, Diouf A, Manga N, Le mo,g V, Reynes J, Koulla Shiro S, Delaporte E

Antiviral Therapy, In press. doi: 10.3851/IMP3097

 

2

Getting pregnant in HIV clinical trials: women’s choice and safety needs. The experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials, HIV Clinical Trials, DOI: 10.1080/15284336.2016.1248624

Serris A1, Zoungrana J2, Diallo M3, Toby R4, Mpoudi Ngolle M5, Le Gac S6, Coutherut J7, Cournil A1, De Beaudrap P7, Koulla-Shiro S4,8, Delaporte E1,9, Ciaffi L1.

HIV Clinical Trials, DOI: 10.1080/15284336.2016.1248624, Pages 1-9 | Published online: 01 Nov 2016

3

HandiVIH. Understanding the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations

De Beaudrap P, Pasquier E, Noelle  A, et al.

Open BMJ 2016, 6(2):e008934

 

4

Higher prevalence of HIV infection among people with disabilities: results of a population-based observational study in Yaoundé, Cameroon (HandiVIH)

De Beaudrap P, Beninguisse G,  Pasquier E, Tchoumkeu A, Touko A, Frida Essomba3, Brus A,  Aderemi T, Hanass-Hancock J, Henning Eide A, Mac-Seing M, Mont D.

En cours de révision

 

5

Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon.

Guichet E1, Aghokeng A2, Eymard-Duvernay S1, Vidal N1, Ayouba A1, Mpoudi Ngole E3, Delaporte E1, Ciaffi L1, Peeters M4.

J Virol Methods. 2016 Sep 5;237:121-126. doi: 10.1016/j.jviromet.2016.09.005. [Epub ahead of print]

 

6

High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.

Guichet E1, Aghokeng A1,2, Serrano L1, Bado G3, Toure-Kane C4, Eymard-Duvernay S1, Villabona-Arenas CJ1,5, Delaporte E1, Ciaffi L1, Peeters M1.

AIDS Res Hum Retroviruses. 2016 Aug 2. [Epub ahead of print]

 

7

Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.

Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, Delacourt C; PAANTHER study group.

Clin Infect Dis. 2016 May 1;62(9):1161-8. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7.

 

8

Cryptococcus neoformans isolates from Yaoundé HIV infected patients exhibited intra individual genetic diversit0y and variation in antifungal susceptibility profiles between isolates from the same patient.
Kammalac Ngouana T, Drakulovski P, Krasteva D, Kouanfack C, Reynes J, Delaporte E, Boyom FF, Mallié M, Bertout S.

J Med Microbiol. 2016 Apr 20. doi: 10.1099/jmm.0.000265. [Epub ahead of print ]

9

Predictors of depression among patients on art in a rural health district in North West Cameroon. 
Asangbeh SL, Sobngwi JL, Ekali GL, Eyoum C, Msellati P.

AIDS Care. 2016 Feb;28(2):205-8. doi: 10.1080/09540121.2015.1074654.

10

Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaoundé, Cameroon.

Galy A1, Ciaffi L, Le Moing V, Eymard-Duvernay S, Abessolo H, Toby R, Ayangma L, Le Gac S, Mpoudi-Etame M, Koulla-Shiro S, Delaporte E, Cournil A; the, Group LS.

Antivir Ther. 2016 Feb 16. doi: 10.3851/IMP3030. [Epub ahead of print]

 

11

First evidence of transmission of an HIV-1 M/O intergroup recombinant virus.

Ngoupo PA, Sadeuh-Mba SA, De Oliveira F, Ngono V, Ngono L, Tchendjou P, Penlap V, Mourez T, Njouom R, Kfutwah A, Plantier JC. 

AIDS. 2016 Jan 2;30(1):1-8.

 

12

How do supply-side factors influence informal payments for healthcare? The case of HIV patients in Cameroon . 

KANKEU HT, BOYER S, FODJO TOUKAM R, ABU-ZAINEH M. 

Int J Health Plann Mgmt 2016; 31: E41–E57. DOI: 10.1002/hpm.2266.

 

13

Estimating mother-to-child HIV transmission rates in Cameroon in 2011: a computer simulation approach.

Nguefack HL1Gwet H2Desmonde S3,4Oukem-Boyer OO5,6Nkenfou C7Téjiokem M8Tchendjou P9Domkam I10Leroy V11,12,13Alioum A14,15;Inserm U897 Modeling Infectious Diseases in Low-Income Countries Study Group.

BMC Infect Dis. 2016 Jan 12;16:11. doi: 10.1186/s12879-016-1336-2.

 

14

Impediments to HIV testing in HIV-infected children and teenagers in Africa: look for them where they are!
Msellati P, Ateba Ndongo F, Hejoaka F, Nacro B.

Med Sante Trop. 2016 Jan-Mar;26(1):10-4. doi: 10.1684/mst.2015.0519.

15

HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Villabona-Arenas CJ, Domyeum J, Mouacha F, Butel C, Delaporte E, Peeters M, Mpoudi-Ngole E, Aghokeng AF.

Infect Genet Evol. 2015 Dec;36:210-6. doi: 10.1016/j.meegid.2015.09.006. Epub 2015 Sep 11.

 

16

Cocirculation of Two env Molecular Variants, of Possible Recombinant Origin, in Gorilla and Chimpanzee Simian Foamy Virus Strains from Central Africa.

Richard L, Rua R, Betsem E, Mouinga-Ondémé A, Kazanji M, Leroy E, Njouom R, Buseyne F, Afonso PV, Gessain A.

J Virol. 2015 Dec;89(24):12480-91. doi: 10.1128/JVI.01798-15. Epub 2015 Oct 7.

 

17

Phylogenetics of HIV-1 subtype G env: Greater complexity and older origins than previously reported.

Tongo M, Essomba RG, Nindo F, Abrahams F, Nanfack AJ, Fokam J, Takou D, Torimiro JN, Mpoudi-Ngole E, Burgers WA, Martin DP, Dorfman JR.

Infect Genet Evol. 2015 Oct;35:9-18. doi: 10.1016/j.meegid.2015.07.017. Epub 2015 Jul 17.

 

18

Feasibility of Routinely Offering Early Combined Antiretroviral Therapy to HIV-infected Infants in a Resource-limited Country: The ANRS-PediaCAM Study in Cameroon.

Tejiokem MC, Warszawski J, Ateba Ndongo F, Tetang Ndiang S, Ndongo JA, Owona F, Ngoupo PA, Tchendjou P, Kfutwah A, Penda IC, Faye A.

Pediatr Infect Dis J. 2015 Oct;34(10):e248-53. doi: 10.1097/INF.0000000000000815.

 

19

Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?

Ateba Ndongo F, Warszawski J, Texier G, Penda I, Tetang Ndiang S, Ndongo JA, Guemkam G, Sofeu CL, Kfutwah A, Faye A, Msellati P, Tejiokem MC; ANRS-PEDIACAM study group.

BMC Pediatr. 2015 Sep 21;15:132. doi: 10.1186/s12887-015-0451-3.

 

20

Near full-length HIV type 1M genomic sequences from Cameroon : Evidence of early diverging under-sampled lineages in the country.

Tongo M, Dorfman JR, Abrahams MR, Mpoudi-Ngole E, Burgers WA, Martin DP.

Evol Med Public Health. 2015 Sep 9;2015(1):254-65. doi: 10.1093/emph/eov022.

 

21

New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon.

Ndawinz JD, Anglaret X, Delaporte E, Koulla-Shiro S, Gabillard D, Minga A, Costagliola D, Supervie V.

Bull World Health Organ. 2015 Aug 1;93(8):521-8. doi: 10.2471/BLT.14.147892. Epub 2015 Jun 1.

 

22

Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa.

Ciaffi L1, Koulla-Shiro S, Sawadogo A, le Moing V, Eymard-Duvernay S, Izard S, Kouanfack C, Ngom Gueye NF, Fobang AA, Reynes J, Calmy A, Delaporte E; 2LADY Study Group.

AIDS. 2015 Jul 31;29(12):1473-81. doi: 10.1097/QAD.0000000000000709.

 

23

Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon.

Boullé C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kazé S, Dontsop M, Mben JM, Koulla-Shiro S, Peytavin G, Spire B, Delaporte E, Laurent C; Stratall ANRS 12110ESTHER Study Group.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):355-64. doi: 10.1097/QAI.0000000000000604.

 

24

Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy].

Suzan-Monti M, Blanche J, Boyer S, Kouanfack C, Delaporte E, Bonono RC, Carrieri PM, Protopopescu C, Laurent C, Spire B; Stratall ANRS 12110/ESTHER Study Group.

HIV Med. 2015 May;16(5):307-18. doi: 10.1111/hiv.12213. Epub 2015 Feb 27.

 

25

Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.

Lê MP, Landman R, Koulla-Shiro S, Charpentier C, Sow PS, Diallo MB, Ngom Gueye NF, Ngolle M, Le Moing V, Eymard-Duvernay S, Benalycherif A, Delaporte E, Girard PM, Peytavin G; on behalf of the DAYANA Study Group.

J Antimicrob Chemother. 2015 May;70(5):1517-21. doi: 10.1093/jac/dku532

26

Origin of the HIV-1 group O epidemic in western lowland gorillas.

D'arc M, Ayouba A, Esteban A, Learn GH, Boué V, Liegeois F, Etienne L, Tagg N, Leendertz FH, Boesch C, Madinda NF, Robbins MM, Gray M, Cournil A, Ooms M, Letko M, Simon VA, Sharp PM, Hahn BH, Delaporte E, Mpoudi Ngole E, Peeters M.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1343-52. doi: 10.1073/pnas.1502022112. Epub 2015 Mar 2.

 

27

Evaluating potential T-cell epitope peptides for detecting HIV-specific T cell responses in a highly diverse HIV-1 epidemic from Cameroon.

Tongo M, Riou C, Crunchant E, Müller TL, Strickland N, Mpoudi-Ngole E, Burgers WA.

AIDS. 2015 Mar 13;29(5):635-9. doi: 10.1097/QAD.0000000000000581.

 

28

Molecular characterization of a new mosaic Simian Immunodeficiency Virus in a naturally infected tantalus monkey (Chlorocebus tantalus) from Cameroon: A challenge to the virus–host co-evolution of SIVagm in African green monkeys

Ayouba A, Njouom R, Chia JR, Ahuka-Mundeke S, A Kfutwah, E Mpoudi Ngole, E Nerrienet, Delaporte E, Peeters M.

Infect Genet Evol. 2015 Mar;30:65-73.doi: 10.1016/j.meegid.2014.12.005

29

Different factors associated with loss to follow-up of infants born to HIV-infected or uninfected mothers: observations from the ANRS 12140-PEDIACAM study in Cameroon.

Sidze LK, Faye A, Tetang SN, Penda I, Guemkam G, Ateba FN, Ndongo JA, Nguefack F, Texier G, Tchendjou P, Kfutwah A, Warszawski J, Tejiokem MC.

BMC Public Health. 2015 Mar 7;15:228. doi: 10.1186/s12889-015-1555-2.

 

30

Investigation of minor species Candida africana, Candida stellatoidea and Candida dubliniensis in the Candida albicans complex among Yaoundé (Cameroon) HIV-infected patients.
Butel C, Ahuka-Mundeke S, Drakulovski P, Krasteva D, Mpoudi-Ngole E, Mallié M, Delaporte E,  Ngouana TK, Krasteva D, Drakulovski P, Toghueo RK, Kouanfack C, Ambe A, Reynes J, Delaporte E, Boyom FF, Mallié M, Bertout S.
Mycoses. 2015 Jan;58(1):33-9. doi: 10.1111/myc.12266

31

Les paradoxes de la pharmaceuticalisation de la santé publique en Afrique: les hépatites virales au Cameroun dans le sillon du VIH / Sida, in J. Collin & P-M David,  De la médicalisation à la pharmaceuticalisation de la société. Selon quels processus et dans quelles limites ?

Fanny Chabrol Presses Universitaires du Québec